Advice
In the absence of a submission from the holder of the marketing authorisation:
venetoclax (Venclyxto®) is not recommended for use within NHSScotland.
Indication under review: In combination with low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice618KB (PDF)
Medicine details
- Medicine name:
- venetoclax (Venclyxto®)
- SMC ID:
- SMC2509
- Indication:
In combination with low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 November 2022